Toxicity testing using hematopoietic stem cells assays

Regenerative Medicine

Volumn 2, Issue 6, 2007, Pages 947-956

  Clarke, E ^a   Pereira, C ^a   Chaney, R ^a   Woodside, S ^a   Eaves, A C ^a,b   Damen, J ^a  

^a StemCell Technologies Inc   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Colony forming cell; Hematopoietic cell; Hematoxicity; Myelosuppression

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CHINESE DRUG; CYTOKINE; FLUOROURACIL; HERBACEOUS AGENT; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; PACLITAXEL; TOXIN;

BONE MARROW CELL; CELL ASSAY; CELL LINE; CELL PROLIFERATION; COLONY FORMING CELL; DECISION MAKING; ERYTHROID CELL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MESENCHYME CELL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING;

ANIMALS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MODELS, BIOLOGICAL; TOXICITY TESTS;

EID: 38049173592     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.2.6.947     Document Type: Review

References (54)

1. Meri S, Baumann M: Proteomics: post-translational modifications, immune responses and current analytical tools. Biomol. Eng. 18, 213-220 (2001).
2. Nielsen ML, Savitski MM, Zubarev RA: Extent of modifications in human proteome, samples and their effect on dynamic range of analysis in shotgun proteomics. Mol. Cell Proteomics 5, 2384-2391 (2006).
3. International Human Genome Sequencing Consortium: Finishing the euchromatic sequence of the human genome. Nature 431 (7011), 931-945 (2004).
4. Kampa D, Cheng J, Kapranov P et al.: Novel RNAs identified from an in-depth analysis of the transcriptome of human chromosomes 21 and 22. Genome Res. 14, 331-342 (2004).
5. Tufts Center for the study of Drug Development: Outlook 2002
6. Gribaldo L, Casati S, Castoldi AF et al.: Comparison of in vitro drug sensitivity of human granulocyte-macrophage progenitors from two different origins: umbilical cord blood and bone marrow. Exp. Hematol. 27, 1593-1598 (1999).
7. Gomez SG, Faircloth G, Lopez-Lazaro L et al.: In vitro hematotoxicity of Aplidine of human bone marrow and cord blood progenitor of cells. Toxicol. In Vitro 15, 347-350 (2001).
8. Pyatt DW, Yang Y, Mehos B et al.: Hematotoxicity of the Chinese herbal medicine Tripterygium wilfordii hook F in CD34-positive human bone marrow cells. Mol. Pharmacol. 57(3), 512-518 (2000).
9. Pessina A, Albella B, Bueren J et al.: Prevalidation of a model for predicting acute neutropenia by colony forming unit Granulocyte/ Macrophage (CFU-GM) assay. Toxicol. In Vitro. 15, 729-740 (2001).
10. Pessina A, Albella B, Bayo M et al.: Application of the GM-CFU assay to predict acute drug-induced neutropenia: An international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive Xenobiotics. Toxicol. Sci. 75(2), 355-367 (2003).
11. Matsumura-Takeda K, Kotosai K, Ozaki A et al.: Rat granulocyte colony-forming Unit (CFU-G) assay for assessment of drug induced hematotoxicity. Toxicol. In Vitro 16(3), 281-288 (2002).
12. van Den Heuvel RL, Lepens H, Schoeters GE: Use of in vitro assays to assess hematotoxic effects on environmental compounds Cell Biol. Toxicol. 17(2), 107-116 (2001).
13. van Den Heuvel RL, Leppens H, Schoeters GE: Lead and catechol and hematotoxicology in vitro using human and murine hematopoietic progenitor cells. Cell Biol. Toxicol. 15, 101-110 (1999).
14. Rio B, Froquet R, Parent-Massin D: In vitro effect of lead acetate on human erythropoietic progenitors. Cell Biol. Toxicol. 17, 41-50 (2001).
15. Sundman-Engberg B, Paul C, Tidefelt U: Effects of cytokines in the toxicity of cytostatic drugs to normal bone marrow cells in vitro. Cancer Chemother. Pharmacol. 42(3), 255-260 (1998).
16. NIH Roadmap ADMET Workshop, Bethesda, June (2004).
17. Crosta GF, Fumarola L, Malerba I, Gribaldo L: Scoring CFU-GM Colonies in vitro by data fusion: A first account. Exp. Hematol. 35, 1-12 (2007).
18. Thomas ED, Lochte HL Jr, Lu WC et al.: Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N. Engl. J. Med. 257, 491-496 (1957).
19. Mathe G, Jammet H, Pendir B: Transfusion et greffes de moelle osseuse homologue chez des humains irradies a haut dause accidentellement. Rev. Fr. Etud. Clin. Biol. 4, 226-238 (1959).
20. Till JE, McCulloch EA: A direct measurement of radiation sensitivity of normal mouse bone marrow cells. Radiat. Res. 14, 313-322 (1961).
21. Bradley TR, Metcalf D: The growth of mouse bone marrow cells in vitro. Aust. J. Exp. Biol. Med. Sci., 44, 287-292 (1966).
22. Pluznik DH, Sachs L: The cloning of normal mast cells in tissue culture. J. Cell. Physiol. 66, 319-324 (1966).
23. Stephenson JR, Axelrad AA, McLeod DL, Shreeve MM: Induction of colonies of hemoglobin-synthesizing cells by erythropoietin in vitro. Proc. Natl Acad. Sci. USA 68, 1542-1556 (1971).
24. Metcalf D, MacDonald HR, Odartchenko N, Sordat B: Growth of mouse megakaryocye colonies in vitro. Proc. Natl Acad. Sci. USA 72(5), 1744-1748 (1975).
25. Friedenstein AJ, Chailakhyan RK, Laliykina KS: The development of fibroblast colonies in monolayer cultures of guinea pig bone marrow and spleen cells. Cell Tissue Kinet. 3, 393-403 (1970).
26. Clarke E, McCann SR: Age dependent in vitro stromal growth. Bone Marrow Transplant. 4, 596-597 (1989).
27. Scopes J, Ismail M, Marks JK et al.: Correction of stromal cell defect after bone marrow transplantation in aplastic anaemia. Br. J. Haematol. 115, 642-652 (2001).
28. Galotto M, Berisso G, Deffino L et al.: Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp. Hematol. 27, 1460-1466 (1999).
29. Dexter TM, Allen TD, Lajtha LG: Conditions controlling the proliferation of hemopoietic stem cells in vitro. Br. J. Haematol. 28, 525-530 (1974).
30. Schofield R: The relationship between the spleen colony forming cell and the haemopoietic stem cell. A hypothesis. Blood Cells 4, 7-25 (1978)
31. Zipori D: Hemopoietic microenvironments. In: Haemopoiesis. Testa NG, Gale RP (Eds). Marcel Dekker Inc. NY, USA and Basel, Switzerland (1988).
32. Lapidot T, Petit I: Current understanding of stem cell mobilization: The role of chemokines, proteolytic enzymes, adhesion molecules, cytokines and stromal cells. Exp. Hematol. 30, 973-981 (2002).
33. Ploemacher RE, van der Sluijs JP, Voerman JS et al.: An in vitro limiting dilution assay of long term repopulating hemaopoietic stem cells in the mouse. Blood 74, 2755-2763 (1989)
34. Sutherland HJ, Eaves CJ, Lansdorp PM et al.: Differential regulation of primitive hematopoitetic cells in long term cultures maintained on genetically engineered murine stromal cells. Blood 78, 666-672 (1991).
35. Bbatia M, Wang JCY, Kapp U et al.: Purification of primitive human hematopoieitic cells capable of repopulating immune-deficient mice. Proc. Natl. Acad. Sci. USA 94, 5320-5325 (1997).
36. Conneally E, Cashman J, Petzer A et al.: Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lymphomyeloid repopulating activity in nonobese diabeticscid/scid mice. Proc. Natl. Acad. Sci. USA 94, 9836 9841 (1997).
37. Dal Negro G, Bonato M, Gribaldo L: In vitro bone marrow Granulocyte-Macrophage progenitor cultures in the assessment of hematopoietic potential of new drugs. Toxicol. In Vitro 17, 95-105 (2001).
38. Parent-Massin D: Relevance of clonogenic assays in hemotoxicology. Cell Biol. Toxicol 17, 87-94 (2001).
39. van Den Heuvel RL, Leppens H, Schoeters GE: Use of in vitro assays to assess hematotoxic effects of environmental compounds. Cell Biol. Toxicol. 17, 107-116 (2001).
40. Casati S, Collotta A, Clothier R et al.: Refinement of the colony forming unit-megakaryocyte (CFU-MK) assay for its application to pharmacotoxicological testing. Toxicol. In Vitro 17, 69-75 (2003).
41. Froquet R, Sibiril Y, Parent-Massin D: Improvement of megakaryocytic progenitor culture for toxicological investigations. Toxicol. In Vitro. 15, 691-699 (2001).
42. Gribaldo L, Malerba I, Colotta A et al.: Inhibition of CFU-E/BFU-E by 3′-azido-3′-deoxythymidine, chlorpropamide, and protoporphirin IX zinc (II): A comparison between direct exposure of progenitor cells and long-term exposure of bone marrow cultures. Toxicol. Sci. 58, 96-101 (2000).
43. Lautraite S, Parent Massin D, Rio B et al.: In vitro toxicity induced by deoxynivalenol (DON) in human and rat granulomonocytic progenitors. Cell Biol. Toxicol. 13, 175-183 (1997).
44. Freund YR, Dabbs J, Creek MR et al.: Synergistic bone marrow toxicity of pyrimethamine and zidovudine in murine in vivo and in vitro models: mechanisms of toxicity. Taxicol Appl. Pbarmacol. 181, 16-26 (2002).
45. Parchment RE: Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity. Environ. Health Perspect. 106(Suppl. 2), 541-557 (1998).
46. Mayhew CN, Phillips JD, Greenberg RN et al.: In vivo and in vitro comparison of short term hematopoietic toxicity between hydroxyurea, trimidox or didox, novel ribonucleotide reductase inhibitors with potential anti-HIV-1 activity. Stem Cells 17 (6), 345-356 (1999).
47. Malerba I, Casati S, Diodovlch C et al.: Inhibition of CFU-E/BFU-E and CFU-GM colony growth by cyclophosphamide, 5-fluorouracil and taxol: development of a high throughput in vitro method. Toxicol. In Vitro 18, 293-300 (2004).
48. Keyes KA, Segovia J C, Hueren JA et al.: Latent hematopoietic stem cell toxicity associated with protracted drug administration. Exp. Hematol. 29, 286-294 (2001).
49. Keyes KA, Albella B. LoRusso PM et al.: Cytotoxic chemotherapy regimens that increased dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond. Clin. Cancer Res. 6, 2474-2481 (2000).
50. Dumenil D, Sainteny F, Frindel F: Some effects of chemotherapeutic drugs on bone marrow stem cells. I. The long term effects of phase specific drugs on mouse bone marrow stem cells. Cancer Chemother. Pharmacol. 2, 197-201 (1979).
51. Aidoudi S, Guigon M, Lebeurier I et al.: vivo effects of platelet factor 4 (PF4) and tetrapeptide AcSDKP on hemopoiesis on mice treated with 5-fluorouracil. Br. J Haematol. 94, 443-448 (1996).
52. Tanaka T, Suda T, Suda J et al.: Stimulatory effects of granulocyte colony-stimulating factor on colony forming unit-spleen differentiation and pre -CFU-S proliferation in mice. Blood 77(12), 2597-2602 (1991).
53. Clarke E, Rice GC, Weeks RS et al.: Lisofylline inhibits transforming growth factor β release and enhances trilineage hematopoietic recovery after 5-fluorouracil treatment in mice. Cancer Res. 56, 105-112 (1996).
54. 1 mice. Stem Cells 16, 144-151 (1998).